Administration of IL-2 into wild-type mice enhanced FBXO38 levels in tumors-infiltrating T cells and down-regulated PD-1 from their surface, resulting in more efficient anti-tumor responses, even when IL-2 simultaneously increased, by activating T cells, PD-1 mRNA transcription [212]. The gene discussed is PDCD1; the disease is neoplasm.